Learn more about genomic advancements and oncology trends taking place around the world. Renowned speakers from the WHO, National Institute of Health, and many more prestigious organizations will share their insights on the latest developments in the field of genetics.
A recent study revealed evidence on the genetic basis of prostate cancer (PCa) predisposition and the importance of germline genetic testing for patients with a positive family history of PCa or men with high-risk or metastatic disease. A systemic review was conducted and the results of this study were published in the journal, Prostate Cancer and Prostatic Diseases.
Impressive progress in biotechnology research and further understanding of cancer pathophysiology has led to the development of new, practical, and innovative drugs through collaborations in multidisciplinary fields including biology, drug metabolism, clinical research, medicinal chemistry, and computational chemistry.
A new variant of genetically modified immune T cell (HLA-independent T cell receptors) that can attack cancer was developed at the Memorial Sloan Kettering (MSK) Cancer Center. It was developed by genetically modifying an individual’s immune T cells and decking them up with special receptors that can detect cancer in the body.
Prof. Dr. Dattatreyudu Nori is a world-renowned Indian radiation oncologist. He was the principal investigator for numerous clinical trials sponsored by the National Cancer Institute and has received countless national and international awards including the Distinguished Alumnus Award of the Memorial Sloan-Kettering Cancer Center Alumni Society.
Cancer treatments usually target cancer that has developed in a specific organ or tissue, like breast or lung cancer. Tumour-agnostic therapy, also known as tissue-agnostic therapy, utilizes the same drug to treat all cancer types that have certain genetic mutations or biomarkers that are targeted by the drug.